Clinical trial · Interventional
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
Multi-omics Evaluation System and Preferred Mode of Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
NCT05584267CI-TRIAL-00077613recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy + immunotherapy | Drug | — | UNRESOLVED |
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- cohort A
- description
- Chemotherapy + immunotherapy; Every three weeks, up to four cycles of chemotherapy
- interventionNames
- Drug: Chemotherapy + immunotherapy
- type
- EXPERIMENTAL
- label
- cohort B
- description
- Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; WBRT, 3 Gy/ time, 10 times in total
- interventionNames
- Radiation: radiotherapy
- Drug: Chemotherapy + immunotherapy
- type
- EXPERIMENTAL
- label
- cohort C
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years of age on day of signing informed consent * Histopathology confirmed non-small cell lung cancer * Asymptomatic brain metastases * EGFR/ALK ROS1 driver gene mutation negative * RECIST 1.1 based available assessment of lesions * ECOG 0-1 * Brain metastases 1-4 * Single lesion ≤4cm Exclusion Criteria: * Patients with contraindication of chemotherapy Pregnant or breast feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.